A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5‐fluorouracil‐induced stomatitis

Cancer

Volumn 65, Issue 8, 1990, Pages 1879-1882

  Loprinzi, Charles L ^a   Cianflone, Shirley G ^b   Dose, Ann Marie ^b   Etzell, Paul S ^b   Burnham, Nora L ^b   Therneau, Terry M ^b   Hagen, LeRoyce ^b   Gainey, Debra K ^b   Cross, Madolyn ^b   Athmann, Laureen M ^b   Fischer, Tammy ^b   O'Connell, Michael J ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FLUOROURACIL;

AGE; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMATITIS;

ALLOPURINOL; COLORECTAL NEOPLASMS; CONSUMER SATISFACTION; DOUBLE-BLIND METHOD; FLUOROURACIL; HUMAN; LEUCOVORIN; MIDDLE AGE; MOUTHWASHES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; STOMATITIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025257240     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19900415)65:8<1879::AID-CNCR2820650834>3.0.CO;2-8     Document Type: Article

References (11)

1. Allopurinol mouthwash and 5‐fluorouracil induced oral toxicity
2. Allopurinol modulation of high dose fluorouracil toxicity
3. Modulation of 5‐fluorouracil toxicity by allopurinol in man
4. Allopurinol modification of the toxicity and antitumor activity of 5‐fluorouracil
5. 5‐Fluorouracil and high‐dose folinic acid as salvage treatment of advanced breast cancer: An update
6. Phase II trial of 5FU + folinic acid (FA) as first line treatment for metastatic breast cancer (Abstr)
7. Allopurinol mouthwash kinetic and stability information based on normal volunteers
8. More flexible sequential and non‐sequential designs in long‐term clinical trials
9. Reduction of oral toxicity of 5‐fluorouracil by allopurinol mouthwashes
10. A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5‐fluorouracil (5FU) for the treatment of advanced colorectal cancer: Experience of the Mayo Clinic and North Central Cancer Treatment Group
11. Prevention of doxorubicininduced hair loss with scalp hypothermia